Epredia Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Epredia's estimated annual revenue is currently $135.6M per year.(i)
  • Epredia's estimated revenue per employee is $155,000

Employee Data

  • Epredia has 875 Employees.(i)
  • Epredia grew their employee count by 1% last year.

Epredia's People

NameTitleEmail/Phone
1
VP North American OperationsReveal Email/Phone
2
VP Global Marketing & Corporate StrategyReveal Email/Phone
3
VP FinanceReveal Email/Phone
4
Head Global LogisticsReveal Email/Phone
5
Controller - North AmericaReveal Email/Phone
6
VP, Commercial Operations - AmericasReveal Email/Phone
7
Human Resources DirectorReveal Email/Phone
8
Commercial Finance DirectorReveal Email/Phone
9
Global Director, Lean Business SystemsReveal Email/Phone
10
Director, Commercial ExcellenceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Epredia?

Epredia was established in July 2019 through an acquisition by PHC Group from Thermo Fisher Scientific. Powered by trusted brands such as Richard-Allan Scientific, Microm, Shandon, Menzel Gläser, LabVision and Erie Scientific, Epredia has a wide breadth of solutions that have and will continue to transform the anatomical pathology market. Today, we’re a global company working to improve patient outcomes by providing groundbreaking technologies. Every product developed has been impacted by generations of employees who are committed to improving lives by enabling pathologists through enhancing precision in cancer diagnostics.

keywords:N/A

N/A

Total Funding

875

Number of Employees

$135.6M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$311.2M8759%N/A
#2
$331.5M8778%N/A
#3
$278.7M877N/AN/A
#4
$399M87711%N/A
#5
$75M8788%N/A